{"nodes":[{"id":"ABCA7 with biomarker-guided dosing","type":"gene"},{"id":"neurodegeneration","type":"disease"}],"edges":[{"source_id":"ABCA7 with biomarker-guided dosing","source_type":"gene","target_id":"neurodegeneration","target_type":"disease","relation":"promoted: CSF Biomarker-Guided ABCA7 Therapeutic Dosing","evidence_strength":0.619,"evidence_sources":"[\"SDA-2026-04-14-gap-pubmed-20260410-180532-e8930cb8\", \"{'claim': 'V1613M shows elevated circulating cholesterol and altered brain lipid composition requiring metabolic monitoring', 'pmid': '38506634'}\", \"{'claim': 'ABCA7-LOF impacts phosphatidylcholine metabolism', 'pmid': '38979214'}\", \"{'claim': 'Plasma GFAP enables population-scale screening for reactive astrocytosis', 'pmid': 'computational:ad_biomarker_registry'}\", \"{'claim': 'CSF/Plasma biomarker panel established: GFAP, YKL-40, p-tau181, p-tau217, neurogranin', 'pmid': 'computational:ad_biomarker_registry'}\", \"{'claim': 'Lecanemab/donanemab efficacy validates amyloid biomarker approach', 'pmid': 'established_clinical'}\"]","analysis_id":"SDA-2026-04-14-gap-pubmed-20260410-180532-e8930cb8","created_at":"2026-04-14T11:26:50-07:00","edge_type":"promoted_hypothesis","source_canonical_id":"abca7_with_biomarker_guided_dosing","target_canonical_id":"ent-rese-6f3dc74d","epistemic_status":"speculative","trust_score":null,"confidence_interval":null,"trust_computed_at":null,"id":"promoted-h-bc635955","trust_confidence_low":0.3,"trust_confidence_high":0.7,"trust_computation_factors":"{}","causal_quality_scorecard":null}],"pagination":{"limit":5000,"offset":0,"total_edges":1,"total_nodes":2,"has_more":false}}